BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week In Review: Jiangsu Aosaikang Pharma Delays China IPO


1/20/2014 5:39:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 18, 2014 --Jiangsu Aosaikang Pharma temporarily delayed its $669 million China IPO, saying it was “relatively large,” which didn’t exactly explain the holdup; Changchun High & New Technology Industries paid $4.8 million for a 25% interest in Dutch vaccine maker Mucosis; Wuhan Kindstar Clinical Diagnostics in-licensed a lung cancer test from Germany’s Epigenomics; Thermo Fisher was OK’d by China for its $13.6 billion acquisition of Life Technologies; TaiGen Biotech of Taiwan and Beijing out-licensed Russian rights for its novel antibiotic to R-Pharm of Russia; China issued additional regulations for conducting IPOs under its new “market-oriented” system; Actavis will quit China because it considers the business environment too difficult and the potential profits too small; GlaxoSmithKline said its China revenues turned higher in the fourth quarter of 2013 after dropping a disastrous 61% in Q3; US-based Neuralstem treated its first patient in a China stem cell trial of a stroke treatment; and EntreMed filed a clinical trial application for a China Phase II trial of its ovarian cancer treatment. More details….

Stock Symbols: (SHE: 300361) (F: ECX, OTC: EPGNY) (NYSE: TMO) (NSDQ: LIFE) (NYSE: ACT) (NYSE: GSK) (NYSE: CUR) (NSDQ: ENMD)

Help employers find you! Check out all the jobs and post your resume.


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES